BioWorld

March 1, 2005

View Archived Issues

Biogen Idec, Elan Plummet On Withdrawal Of Tysabri

Two serious adverse events - one ending in death - was enough for Biogen Idec Inc. and Elan Corp. plc to suspend marketing of their multiple sclerosis drug, Tysabri, just three months after FDA approval. (BioWorld Today) Read More

Tercica Completes Increlex NDA For IGF-1 Deficient Short Stature

Read More

In CF, Smaller Promoter Makes A Better Gene Therapy Vehicle

Read More

With Partner Re-evaluating, Phytopharm Pulls Funding

Read More

Other News To Note

Read More